Praxis Precision Medicines, Inc. Q1 FY2026 earnings call

Marcio Souza discussed continued execution across portfolio with four late-stage assets, NDAs accepted by FDA for some drugs, ramping up commercial efforts, completion of Emerald study enrollment, progress in clinical programs including vormetrogene and alginersin, key hires in commercial organization, and launch preparations. Tim Kelly provided financial summary with operating expenses, cash used in operations, and cash position as of March 31, 2026

Discussed progress across product segments including Ulexa with NDA accepted by FDA, epilepsy programs with NDA accepted and recruitment in Emerald study, vormetrogene with upcoming study results, and alginersin with positive trial results. Financials mentioned operating expenses and cash position but segment performance focus on program progress

Expect top-line results from Emerald study in 4Q 2026, PowerOne study for vormetrogene later this quarter, completion of Power2 study later in year, and preparations for commercial launches of elixir-cultamide and relutrigine within next eight months. Cash expected to fund operations into 2028

None explicitly discussed in detail

Q: Questions about Emerald study data, vormetrogene readout, Ulexa regulatory interactions, etc.

A: Marcio and other executives answered regarding study details, expectations, regulatory communication, patient population heterogeneity, commercialization plans, etc.